Tesamorelin

Tesamorelin is a synthetic form of growth hormone-releasing hormone (GHRH) designed to stimulate the body's own production of growth hormone (GH) and a related hormone called IGF-1. It's modified to last longer in the body, allowing for once-daily injections to effectively boost natural GH pulses.

Tesamorelin was approved in 2010 specifically to reduce excess abdominal fat associated with HIV-related lipodystrophy. It works by reducing visceral fat (fat around organs) while generally preserving subcutaneous fat, and it can also improve cholesterol and triglyceride levels.

Beyond its role in lipodystrophy, Tesamorelin has shown benefits in conditions like nonalcoholic fatty liver disease (NAFLD) in people with HIV by reducing liver fat and inflammation markers, without negatively impacting insulin sensitivity.

As with any treatment affecting growth hormone, careful monitoring of IGF-1 levels is recommended.

Significant Visceral Fat Reduction: Clinically proven to reduce deep abdominal fat. (Human Study)
Improved Cholesterol and Triglycerides: Positively affects blood fat levels, including triglycerides and cholesterol ratios. (Human Study)
Maintains Body Shape: Reduces abdominal fat without causing significant loss of fat under the skin, which can improve body image. (Human Study)
Liver Health Benefits: In HIV-positive individuals with fatty liver disease, it can decrease liver fat and reduce inflammation. (Human Study)
No Worsening of Insulin Sensitivity: Does not appear to negatively impact blood sugar control, even with increased growth hormone activity. (Human Study)
Long-Term Effectiveness: The fat-reducing effects can be maintained with continued treatment. (Human Study)
Natural GH Stimulation: Encourages the body to release its own growth hormone in a natural, pulsed manner, which may have fewer off-target risks compared to direct GH injections. (Lab Study)
Modern Formulations Available: Newer, concentrated versions are being developed to support its use. (Regulatory Document)

Falutz, J., et al. (2007). Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV. New England Journal of Medicine, 357(23), 2359–2370.
Stanley, T.L., et al. (2019). Effects of Tesamorelin on Nonalcoholic Fatty Liver Disease in People with HIV. The Lancet HIV, 6(12), e821–e830.
Fourman, L.T., et al. (2020). Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight, 5(16), e138099.
FDA Label: EGRIFTA (tesamorelin) for injection. Prescribing Information.
LiverTox: Tesamorelin. National Institutes of Health.

$68.00

Per Unit

Out of stock